Astellas launched its unsolicited $3.5 billionr bid for the U.S. biotech company OSI Pharmaceuticals and filed a lawsuit to protect the offer from challenges.
The business secretary called for a wide-ranging review of U.K. takeover law, the latest sign that the decades-long mantra that foreign ownership is neutral for domestic companies is being challenged in Britain.
